中国医药
中國醫藥
중국의약
CHINA MEDICINE
2012年
9期
1069-1071
,共3页
戚宇飞%刘甚红%王莉%古丽娜尔·阿德哈木
慼宇飛%劉甚紅%王莉%古麗娜爾·阿德哈木
척우비%류심홍%왕리%고려나이·아덕합목
咳嗽变异型哮喘%沙美特罗/丙酸氟替卡松%孟鲁司特钠%肺功能
咳嗽變異型哮喘%沙美特囉/丙痠氟替卡鬆%孟魯司特鈉%肺功能
해수변이형효천%사미특라/병산불체잡송%맹로사특납%폐공능
Cough variant asthma%Salmeterol/fluticasone propionate%Montelukast soudium%Pulmonary function
目的 观察沙美特罗丙酸氟替卡松联合孟鲁司特钠治疗成人咳嗽变异型哮喘的疗效.方法 采用完全随机对照试验方法将93例咳嗽变异型哮喘患者分为3组各31例,观察组吸入沙美特罗/丙酸氟替卡松(50 μg/250 μg)1吸,早晚各1次,孟鲁司特钠10 mg/次,顿服,共8周.沙美特罗/丙酸氟替卡松组吸入沙美特罗/丙酸氟替卡松(50 μg/250μg)1吸,早晚各1次,共8周.孟鲁司特钠组服用孟鲁司特钠10 mg/次,顿服,共8周.比较3组患者症状改善和肺功能变化情况.结果 治疗后症状积分均较治疗前低,差异有统计学意义(P＜0.05),3组组间差异有统计学意义(P＜0.05).8周治疗后观察组、沙美特罗/丙酸氟替卡松组和孟鲁司特钠组第1秒用力呼气容积(FEV1)、FEV1占预计值的百分比(FEV1％)、呼气峰流速(PEF)与治疗前比较差异均有统计学意义(均P＜0.05)；治疗后观察组FEV1、FEV1％、PEF高于沙美特罗/丙酸氟替卡松组及孟鲁司特钠组,差异均有统计学意义[ FEV1:(1.65±0.52)L比(1.52±0.63)L,(1.46±0.53)L;FEV1％:(64.41±10.31)％比(62.81±11.03)％,(59.02±11.19)％; PEF:(5.24±1.15) L/min比(6.10±1.28) L/min,(6.62±1.00) L/min,均P＜0.05].结论 沙美特罗/丙酸氟替卡松与孟鲁司特钠联合应用治疗咳嗽变异型哮喘疗效优于单用沙美特罗/丙酸氟替卡松或孟鲁司特钠.
目的 觀察沙美特囉丙痠氟替卡鬆聯閤孟魯司特鈉治療成人咳嗽變異型哮喘的療效.方法 採用完全隨機對照試驗方法將93例咳嗽變異型哮喘患者分為3組各31例,觀察組吸入沙美特囉/丙痠氟替卡鬆(50 μg/250 μg)1吸,早晚各1次,孟魯司特鈉10 mg/次,頓服,共8週.沙美特囉/丙痠氟替卡鬆組吸入沙美特囉/丙痠氟替卡鬆(50 μg/250μg)1吸,早晚各1次,共8週.孟魯司特鈉組服用孟魯司特鈉10 mg/次,頓服,共8週.比較3組患者癥狀改善和肺功能變化情況.結果 治療後癥狀積分均較治療前低,差異有統計學意義(P＜0.05),3組組間差異有統計學意義(P＜0.05).8週治療後觀察組、沙美特囉/丙痠氟替卡鬆組和孟魯司特鈉組第1秒用力呼氣容積(FEV1)、FEV1佔預計值的百分比(FEV1％)、呼氣峰流速(PEF)與治療前比較差異均有統計學意義(均P＜0.05)；治療後觀察組FEV1、FEV1％、PEF高于沙美特囉/丙痠氟替卡鬆組及孟魯司特鈉組,差異均有統計學意義[ FEV1:(1.65±0.52)L比(1.52±0.63)L,(1.46±0.53)L;FEV1％:(64.41±10.31)％比(62.81±11.03)％,(59.02±11.19)％; PEF:(5.24±1.15) L/min比(6.10±1.28) L/min,(6.62±1.00) L/min,均P＜0.05].結論 沙美特囉/丙痠氟替卡鬆與孟魯司特鈉聯閤應用治療咳嗽變異型哮喘療效優于單用沙美特囉/丙痠氟替卡鬆或孟魯司特鈉.
목적 관찰사미특라병산불체잡송연합맹로사특납치료성인해수변이형효천적료효.방법 채용완전수궤대조시험방법장93례해수변이형효천환자분위3조각31례,관찰조흡입사미특라/병산불체잡송(50 μg/250 μg)1흡,조만각1차,맹로사특납10 mg/차,돈복,공8주.사미특라/병산불체잡송조흡입사미특라/병산불체잡송(50 μg/250μg)1흡,조만각1차,공8주.맹로사특납조복용맹로사특납10 mg/차,돈복,공8주.비교3조환자증상개선화폐공능변화정황.결과 치료후증상적분균교치료전저,차이유통계학의의(P＜0.05),3조조간차이유통계학의의(P＜0.05).8주치료후관찰조、사미특라/병산불체잡송조화맹로사특납조제1초용력호기용적(FEV1)、FEV1점예계치적백분비(FEV1％)、호기봉류속(PEF)여치료전비교차이균유통계학의의(균P＜0.05)；치료후관찰조FEV1、FEV1％、PEF고우사미특라/병산불체잡송조급맹로사특납조,차이균유통계학의의[ FEV1:(1.65±0.52)L비(1.52±0.63)L,(1.46±0.53)L;FEV1％:(64.41±10.31)％비(62.81±11.03)％,(59.02±11.19)％; PEF:(5.24±1.15) L/min비(6.10±1.28) L/min,(6.62±1.00) L/min,균P＜0.05].결론 사미특라/병산불체잡송여맹로사특납연합응용치료해수변이형효천료효우우단용사미특라/병산불체잡송혹맹로사특납.
Objective To observe the efficacy of salmeterol/fluticasone propionate combined with montelukast soudium in treatment of adult patients with cough variant asthma.Methods Ninety-three patients were randomly divided into three groups. The observation group inhaled salmeterol/fluticasone propionate (50 μg/250 μg)and took montelukast soudium 10 mg one time for eight weeks.Two other control groups:one inhaled salmeterol/fluticasone propionate (salmeterol/fluticasone propionate group)and the other took montelukast soudium (montelukast soudium group).The improvement of symptom and changes of pulmonary function in three groups were compared.Results After treatment the symptom scores were all lower (P＜0.05 ),the difference was statistically significant among the 3 groups (P＜0.05 ).After 8 weeks of treatment,forced expiratory volume in one second (FEV1 ),FEV1 percentages of predicted (FEV1％ ),peak expiratory flow (PEF)in the observation group,salmeterol/fluticasone propionate group and montelukast soudium group had significant differences (all P＜0.05 );after treatment,FEV1,FEV1％ and PEF in observation group were all higher than those in the salmeterol/fluticasone propionate group and montelukast soudium group,the differences were statistically significant [ FEV:(1.65±0.52)Lvs(1.52±0.63)L,(1.46±0.53)L;FEV1％:(64.41±10.31)％ vs(62.81±11.03)％,(59.02±11.19)％;PEF:(5.24±1.15)L/min vs (6.10±1.28)L/min,(6.62±1.00)L/min,all P＜0.05 ].Conclusion The salmeterol/fluticasone propionate combined with montelukast soudium is superior to the salmeterol / fluticasone propionate or montelukast soudium in treatment of cough variant asthma.
